• 1. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 2. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 3. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 4. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 5. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699

Introduction to 3-Azabicyclo[3.2.1]octane, 1-methyl- (CAS No. 88799-00-2) and Its Emerging Applications in Chemical Biology

3-Azabicyclo[3.2.1]octane, 1-methyl-, identified by the Chemical Abstracts Service Number (CAS No.) 88799-00-2, is a heterocyclic compound that has garnered significant attention in the field of chemical biology due to its unique structural framework and potential biological activities. This bicyclic amine derivative features a nitrogen atom embedded within a three-membered ring fused to two six-membered rings, creating a rigid scaffold that mimics natural products and pharmacophores. The presence of a methyl group at the 1-position further modulates its chemical properties, making it a versatile scaffold for drug discovery and molecular recognition.

The structural motif of 3-Azabicyclo[3.2.1]octane, 1-methyl- is reminiscent of several bioactive natural products, including terpenes and alkaloids, which have been extensively studied for their pharmacological effects. The strained ring system in this compound imparts high reactivity and conformational flexibility, enabling it to interact with biological targets in unique ways. This feature has made it a promising candidate for the development of novel therapeutic agents, particularly in the areas of oncology, neurology, and anti-inflammatory treatments.

In recent years, computational chemistry and molecular modeling have played a pivotal role in understanding the interactions between 3-Azabicyclo[3.2.1]octane, 1-methyl- and biological macromolecules. Studies have demonstrated that the compound can bind to enzymes and receptors with high affinity, often through hydrogen bonding networks and hydrophobic interactions. The nitrogen atom in the bicyclic structure serves as a key hydrogen bond acceptor, while the methyl group at the 1-position can engage in van der Waals interactions or π-stacking with aromatic residues in proteins. These insights have guided the design of derivatives with enhanced binding affinity and selectivity.

One of the most compelling aspects of 3-Azabicyclo[3.2.1]octane, 1-methyl- is its potential as a scaffold for developing small-molecule inhibitors targeting protein-protein interactions (PPIs). PPIs are crucial mediators of cellular signaling pathways and are implicated in numerous diseases, including cancer and autoimmune disorders. The rigid bicyclic core of this compound provides a stable platform for designing molecules that can disrupt or modulate PPIs by occupying specific binding pockets on target proteins. Recent advances in fragment-based drug design have leveraged this scaffold to identify lead compounds with promising preclinical profiles.

The synthesis of 3-Azabicyclo[3.2.1]octane, 1-methyl- presents both challenges and opportunities for organic chemists. Traditional synthetic routes often involve multi-step processes with moderate yields, but recent innovations in catalytic methods have improved efficiency significantly. Transition-metal-catalyzed cyclizations and ring-forming reactions have been particularly effective in constructing the strained bicyclic system without excessive racemization or decomposition. These advancements have not only simplified the synthesis but also opened avenues for exploring libraries of derivatives through combinatorial chemistry approaches.

In the realm of medicinal chemistry, derivatives of 3-Azabicyclo[3.2.1]octane, 1-methyl- have been investigated for their ability to modulate ion channels and receptors involved in neurological disorders. For instance, analogs with modifications at the nitrogen or methyl positions have shown potential as GABA receptor modulators, which could be relevant for treating epilepsy or anxiety-related conditions. Similarly, structural variations have been explored to target nicotinic acetylcholine receptors (nAChRs), which are implicated in cognitive function and addiction.

The growing interest in 3-Azabicyclo[3.2.1]octane, 1-methyl- has also spurred research into its role as a chiral building block for enantioselective synthesis. The presence of multiple stereocenters in this compound allows for the preparation of enantiomerically pure derivatives using asymmetric catalysis or chiral auxiliaries. Such enantiomerically enriched compounds are highly sought after in drug development due to their improved pharmacokinetic properties and reduced side effects.

Biocatalytic approaches have further enhanced the accessibility of 3-Azabicyclo[3.2.1]octane, 1-methyl- derivatives by enabling stereoselective transformations under mild conditions. Enzymes such as cytochrome P450 monooxygenases and flavin-containing monooxygenases (FMOs) have been employed to introduce functional groups at specific positions on the scaffold while preserving stereochemical integrity. This biocatalytic strategy not only improves synthetic efficiency but also aligns with green chemistry principles by reducing reliance on harsh reagents.

The versatility of 3-Azabicyclo[3.2.methyl- has also been exploited in materials science applications beyond pharmaceuticals。 Its rigid framework makes it suitable for designing supramolecular assemblies or polymers with tailored properties。 For example， metal-organic frameworks (MOFs) incorporating this scaffold exhibit unique porosity characteristics， making them promising candidates for gas storage or separation applications。 Additionally， its ability to form stable hydrogen bonds has been utilized to develop self-assembling systems with potential applications in nanotechnology。

Future directions in research on 3-Azabicyclo[3.methyl- are likely to focus on expanding its biological activity profile through structure-based drug design。 High-resolution crystal structures of protein-ligand complexes will provide critical insights into binding mechanisms， enabling rational modifications to improve potency， selectivity， and pharmacokinetic properties。 Furthermore， advances in artificial intelligence-driven drug discovery platforms may accelerate the identification of novel derivatives with optimized therapeutic profiles。

In conclusion， 3-Azabicyclo[3.methyl- (CAS No.).88799-00-2) represents a structurally fascinating compound with broad potential applications across chemical biology， medicinal chemistry， and materials science。 Its unique scaffold， coupled with recent advances in synthetic methodologies， computational modeling， and biocatalysis， positions it as a valuable tool for developing innovative solutions to complex biological challenges。 As research continues to uncover new possibilities， this heterocyclic amine derivative is poised to make significant contributions to science and medicine。

• 7144-05-0(4-(Aminomethyl)piperidine)
• 7149-42-0((1-methylpiperidin-4-yl)methanamine)
• 65017-57-4(4-(Aminomethyl)-1-(n-butyl)piperidine)
• 1193-12-0(3,3-Dimethylpiperidine)
• 176-64-7(8-Azaspiro[4.5]decane)
• 13603-14-0(3-Propylpiperidine)
• 35794-11-7(3,5-Dimethylpiperidine)
• 14446-75-4(cis-3,5-Dimethylpiperidine)
• 126579-26-8(methyl[(piperidin-4-yl)methyl]amine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)